Blog _Blog What is eCTD v4.0? Read more » April 17, 2026 _Blog Key points of the labelling of medicinal products in France Read more » April 8, 2026 _Blog Registration of an active substance in Europe: CEP versus ASMF Read more » April 7, 2026 _Blog EMA innovation support: How does the EMA support innovative projects? Read more » March 27, 2026 _Blog CIP Coding for Medicines Read more » March 20, 2026 _Blog The Nitrosamine Risk: A Major Challenge for the Pharmaceutical Industry Read more » March 16, 2026 _Blog Implementation of ICH Q12 in Europe: where are we now? Read more » March 5, 2026 _Blog Centralised Procedure Read more » February 13, 2026 _Blog Do “over the counter” medicines exist in France? Read more » February 13, 2026 _Blog Clinical Trials versus Research Involving Human Subjects (RIPH): How Are Pharmaceutical Companies Affected? Read more » February 3, 2026 _Blog Understanding EUDAMED: The European Database on Medical Devices Read more » January 28, 2026 _Blog New ICH M4Q(R2) guidelines: towards a paradigm shift for Module 2.3 and 3 formats Read more » January 16, 2026 Page1 Page2 Page3 Page4 Page5
_Blog EMA innovation support: How does the EMA support innovative projects? Read more » March 27, 2026
_Blog The Nitrosamine Risk: A Major Challenge for the Pharmaceutical Industry Read more » March 16, 2026
_Blog Clinical Trials versus Research Involving Human Subjects (RIPH): How Are Pharmaceutical Companies Affected? Read more » February 3, 2026
_Blog New ICH M4Q(R2) guidelines: towards a paradigm shift for Module 2.3 and 3 formats Read more » January 16, 2026
